• Acute Myeloid Leukemia

Dr Saar Gill is an associate professor of medicine in the division of hematology-oncology at the University of Pennsylvania. Dr Gill trained in clinical hematology in his native Australia, followed by a post-doctoral fellowship at Stanford University. Since 2011 he has been working on developing genetically engineered immune cells for the treatment of cancer. Dr Gill is a physician-scientist who places a strong emphasis on translational research, and concepts developed in his laboratory have already led to several clinical trials for the treatment of hematologic malignancies. Dr. Gill co-founded Carisma Therapeutics with his first graduate student, Michael Klichinsky, and recently co-founded Interius Biotherapeutics. He is a member of the American Society of Hematology Scientific Sub-Committee on Myeloid Neoplasia, elected to the American Society of Clinical Investigation, a past chair of the Cancer and Gene Therapy committee of the American Society of Gene & Cell Therapy, and a co-chair of the American Society of Transplantation and Cell Therapy’s Women, Under-represented Minorities and LGBTQ Special Interest Group.